Rheumatoid Arthritis
Conditions
Brief summary
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.
Interventions
DRUGSHR0302
The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
DRUGPlacebo
The placebo group will take drugs orally for 24 weeks, and then switch to SHR0302 dose1 for 28 weeks, in the meanwhile, SHR0302 dose1 group and SHR0302 dose2 group will continue taking drugs for the whole 52 weeks.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Provide signed informed consent. * RA diagnosis consistent with the 2010 ACR/EULAR criteria; * Moderate to severe RA defined by 6 or more tender joints, 6 or more swollen joints (68- or 66-joint count), and an ESR of 28 mm/h or greater or a CRP level greater than 5mg/L. * Subjects were required to have an inadequate response to treatment with csDMARDs before baseline. * If subjects are taking permitted csDMARDs or low-dose corticosteroid orally at baseline , the stable doses should have lasted for more than 4 weeks already. * BMI ≥18 kg/m2
Exclusion criteria
* Pregnant women or refuse to receive contraception during the study. * Lab abnormality within 4 weeks of randomization as follows: WBC count \<3.0×10\^9/L；neutrophil count\<1.5×10\^9/L;hemoglobin level\<90.0 g/L ; platelet count \<100×10\^9/L; AST or ALT levels greater than the upper limit of normal; HBsAg or HCV or HIV antibody positivity. * History of another autoimmune rheumatic disease ; history of cancer or infection including tuberculosis and hepatitis; history of important cardiovascular events or thrombotic diseases. * Previous treatment with JAK inhibitor or cytotoxic drugs; bDMARDs within 6 months of randomization; other strong immunosuppressants within 3 months of randomization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ACR20 response rate at week 24 | Week 24 | Response rate of 20% improvement in American College of Rheumatology (ACR20) criteria at week 24 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ACR50 response rate at week 24 and week 52 | Week 24 and week 52 | Response rate of 50% improvement in American College of Rheumatology (ACR50) criteria at week 24 and week 52 |
| ACR70 response rate at week 24 and week 52 | Week 24 and week 52 | Response rate of 70% improvement in American College of Rheumatology (ACR70) criteria at week 24 and week 52 |
| Change from baseline in HAQ-DI score at week 24 and week 52 | Week 24 and week 52 | Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 24 and week 52 |
| ACR20 response rate at week 52 | Week 52 | Response rate of 20% improvement in American College of Rheumatology (ACR20) criteria at week 52 |
| DAS28-CRP <2.6 proportion at week 24 and week 52 | Week 24 and week 52 | Disease Activity Score for 28-joint counts based on the c-reaction protein (DAS28-CRP) of less than 2.6 |
| DAS28-CRP≤3.2 proportion at week 24 and week 52 | Week 24 and week 52 | Disease Activity Score for 28-joint counts based on the c-reaction protein (DAS28-CRP) of equal to and less than 3.2 |
| Change from baseline in SF-36 score at week 24 and week 52 | Week 24 and week 52 | Change from baseline in the medical outcomes study 36-Item Short-Form Health Survey (SF-36) score at week 24 and week 52 |
Countries
China
Outcome results
None listed